12.49
-0.01(-0.08%)
Currency In USD
| Previous Close | 12.5 |
| Open | 12.53 |
| Day High | 12.68 |
| Day Low | 12.2 |
| 52-Week High | 17.94 |
| 52-Week Low | 4.88 |
| Volume | 302,168 |
| Average Volume | 186,355 |
| Market Cap | 271.95M |
| PE | -4.94 |
| EPS | -2.53 |
| Moving Average 50 Days | 13.6 |
| Moving Average 200 Days | 12.11 |
| Change | -0.01 |
If you invested $1000 in Aardvark Therapeutics, Inc. Common Stock (AARD) since IPO date, it would be worth $872.82 as of February 28, 2026 at a share price of $12.49. Whereas If you bought $1000 worth of Aardvark Therapeutics, Inc. Common Stock (AARD) shares 6 months ago, it would be worth $1,471.14 as of February 28, 2026 at a share price of $12.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
GlobeNewswire Inc.
3 hours ago
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Feb 13, 2026 1:00 PM GMT
SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the
Aardvark Therapeutics Announces Leadership Appointments
GlobeNewswire Inc.
Feb 12, 2026 1:00 PM GMT
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the